Study of DA-9801 to Treat Diabetic Neuropathic Pain

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
This is a Phase II dose-ranging study to evaluate the effectiveness and safety of DA-9801 in the treatment of pain associated with diabetic neuropathy. Subjects will receive either 300mg, 600mg, 900mg or placebo, three times daily for eight weeks. During treatment, pain score by Likert numerical rating scale, Patient Global Impression of Improvement (PGI-I) and Change in Clinical Global Impression(CGI)are accessed to evaluate the effectiveness.
Epistemonikos ID: 3eca8af1852da6c04fcb9fef0fdc3f167de2594b
First added on: May 11, 2024